

John E Levine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5082324/publications.pdf>

Version: 2024-02-01

125
papers

10,889
citations

43973

48
h-index

31759

101
g-index

129
all docs

129
docs citations

129
times ranked

10631
citing authors

#	ARTICLE	IF	CITATIONS
1	Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. Bone Marrow Transplantation, 2022, 57, 302-303.	1.3	1
2	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. Bone Marrow Transplantation, 2022, 57, 445-452.	1.3	3
3	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. Journal of Clinical Oncology, 2022, 40, 2023-2035.	0.8	36
4	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Advances, 2022, 6, 3707-3715.	2.5	9
5	Comparison of total body irradiation & versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 2021, 106, 1839-1845.	1.7	13
6	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood, 2021, 137, 983-993.	0.6	20
7	Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease. BioDrugs, 2021, 35, 19-33.	2.2	11
8	Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. Pediatric Blood and Cancer, 2021, 68, e28946.	0.8	3
9	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Journal of Clinical Oncology, 2021, 39, 1865-1877.	0.8	111
10	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. Journal of Clinical Oncology, 2021, 39, 1878-1887.	0.8	14
11	Abstract 510: Impact of tisagenlecleucel product attributes on clinical outcomes in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). , 2021, , .		0
12	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplantation and Cellular Therapy, 2021, 27, 885-907.	0.6	12
13	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 988.e1-988.e7.	0.6	10
14	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Advances, 2021, 5, 4980-4991.	2.5	12
15	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: 1b. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	0.6	21
16	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
17	Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. Bone Marrow Transplantation, 2021, 56, 2869-2870.	1.3	3
18	MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. Blood, 2021, 138, 2955-2955.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3900-3900.	0.6	0
20	Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	29
21	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. <i>Haematologica</i> , 2020, 105, 1879-1886.	1.7	83
22	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e94-e100.	2.0	3
23	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	3.3	16
24	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	0.6	56
25	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with Î±-1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	2.5	24
26	3424 Serial Biomarker Monitoring Predicts Long Term Outcomes in Acute Graft Versus Host Disease. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 114-114.	0.3	0
27	Disease Risk Index Predicts Relapse in Children Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S109-S110.	2.0	2
28	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	2.5	63
29	Biomarkers in acute graft-versus-host disease: new insights. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071989135.	1.1	25
30	Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 712-719.	2.0	28
31	Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. <i>Blood</i> , 2019, 134, 292-292.	0.6	19
32	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 367-367.	0.6	0
33	Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1922-1922.	0.6	0
34	Chemokines: a novel chronic GVHD target. <i>Blood</i> , 2018, 131, 1636-1638.	0.6	1
35	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
36	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140

#	ARTICLE	IF	CITATIONS
37	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2018, 103, 531-539.	1.7	25
38	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
39	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2018, 24, 1504-1506.	15.2	393
40	Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 6175-6184.	3.2	170
41	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.	2.5	21
42	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	2.5	27
43	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656.	2.0	18
44	EBMT~NIH~CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	1.3	243
45	Survival signal REG3 β prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 4970-4979.	3.9	94
46	Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3044-3044.	0.8	3
47	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356.	0.6	0
48	Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 522-528.	2.0	49
49	Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 711-726.	8.2	110
50	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
51	Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802. <i>Blood</i> , 2017, 130, 72-72.	0.6	3
52	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
53	Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 469-484.	0.5	4
54	Development of a biomarker scoring system for use in graft-versus-host disease. <i>Biomarkers in Medicine</i> , 2016, 10, 793-795.	0.6	7

#	ARTICLE	IF	CITATIONS
55	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016, 128, 2561-2567.	0.6	174
56	Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 862-868.	2.0	40
57	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
58	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 54-60.	2.0	12
59	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. <i>Blood</i> , 2016, 128, 2801-2801.	0.6	58
60	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	0.6	1
61	The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 899-899.	0.6	10
62	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510.	0.6	0
63	Revisiting mycophenolate mofetil for steroidâ€refractory acute graftâ€versusâ€host disease: Is higher dosing effective in children?. <i>Pediatric Transplantation</i> , 2015, 19, 582-583.	0.5	0
64	National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis. <i>Transfusion Medicine Reviews</i> , 2015, 29, 62-70.	0.9	31
65	A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. <i>Lancet Haematology</i> , 2015, 2, e21-e29.	2.2	232
66	Predictive Value of Bronchiolitis Obliterans Syndrome Stage Op in Chronic Graft-versus-Host Disease of the Lung. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1127-1131.	2.0	43
67	Extracorporeal photopheresis in prevention and treatment of acute GVHD. <i>Transfusion and Apheresis Science</i> , 2015, 52, 151-156.	0.5	19
68	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
69	Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. <i>Annals of Hematology</i> , 2015, 94, 1033-1041.	0.8	9
70	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 913.	3.8	333
71	Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 142-150.	2.0	66
72	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 67-73.	2.0	62

#	ARTICLE	IF	CITATIONS
73	Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Blood</i> , 2015, 126, 1907-1907.	0.6	1
74	A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study. <i>Blood</i> , 2015, 126, 619-619.	0.6	5
75	Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation. <i>European Journal of Human Genetics</i> , 2014, 22, 715-723.	1.4	5
76	Improved accuracy of acute graft-versus-host disease staging among multiple centers. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 283-287.	0.7	23
77	Metagenomic Analysis of the Stool Microbiome in Patients Receiving Allogeneic Stem Cell Transplantation: Loss of Diversity Is Associated with Use of Systemic Antibiotics and More Pronounced in Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 640-645.	2.0	444
78	Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. <i>Blood</i> , 2014, 123, 3655-3663.	0.6	112
79	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95.	5.1	113
80	Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2062-2066.	2.0	11
81	Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1426-1434.	2.0	20
82	Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1407-1417.	2.0	80
83	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793.	0.6	94
84	Less (bacterial diversity) is more (deaths). <i>Blood</i> , 2014, 124, 995-996.	0.6	2
85	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	0.6	92
86	ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death. <i>New England Journal of Medicine</i> , 2013, 369, 529-539.	13.9	339
87	Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 481-485.	2.0	6
88	Advances in predicting acute <sc>GVHD</sc>. <i>British Journal of Haematology</i> , 2013, 160, 288-302.	1.2	96
89	Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1044-1047.	0.8	14
90	Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. <i>Haematologica</i> , 2013, 98, 179-184.	1.7	84

#	ARTICLE	IF	CITATIONS
91	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013, 121, 197-206.	0.6	123
92	Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. <i>Blood</i> , 2013, 122, 1505-1509.	0.6	132
93	A Biomarker-Based Grading System At Onset Of GvHD Predicts NRM Better Than The Modified Glucksberg Grading System. <i>Blood</i> , 2013, 122, 145-145.	0.6	7
94	Plasma biomarkers of lower gastrointestinal and liver acute GVHD. <i>Blood</i> , 2012, 119, 2960-2963.	0.6	122
95	Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. <i>Blood</i> , 2012, 119, 3854-3860.	0.6	163
96	Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1265-1272.	2.0	181
97	TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1525-1532.	2.0	50
98	Clinical Applications for Biomarkers of Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S116-S124.	2.0	51
99	Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1044-1054.	2.0	48
100	Have we made progress in the treatment of GVHD?. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 473-478.	0.7	11
101	Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. <i>Blood</i> , 2011, 118, 6702-6708.	0.6	277
102	Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin. <i>Science Translational Medicine</i> , 2010, 2, 13ra2.	5.8	215
103	Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 263-272.	2.0	165
104	Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 421-429.	2.0	32
105	Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 907-914.	2.0	119
106	Graft-versus-Host Disease Treatment: Predictors of Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1693-1699.	2.0	89
107	Graft-versus-host disease. <i>Lancet, The</i> , 2009, 373, 1550-1561.	6.3	2,093
108	A biomarker panel for acute graft-versus-host disease. <i>Blood</i> , 2009, 113, 273-278.	0.6	348

#	ARTICLE	IF	CITATIONS
109	Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i> , 2009, 114, 511-517.	0.6	217
110	Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 759-765.	2.0	36
111	Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1017-1021.	2.0	65
112	Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. <i>Blood</i> , 2008, 111, 2470-2475.	0.6	183
113	Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. <i>Blood</i> , 2008, 112, 1539-1542.	0.6	128
114	The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3073-3081.	0.6	117
115	BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD). <i>Blood</i> , 2008, 112, 55-55.	0.6	3
116	A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTTC) study. <i>Blood</i> , 2007, 110, 4584-4587.	0.6	45
117	A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease (GVHD) Predicts Long Term Survival.. <i>Blood</i> , 2007, 110, 38-38.	0.6	1
118	Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.. <i>Blood</i> , 2007, 110, 39-39.	0.6	0
119	Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM.. <i>Blood</i> , 2006, 108, 37-37.	0.6	1
120	Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 680-687.	2.0	89
121	Survival Following Etanercept Therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 354-354.	0.6	5
122	The Use of Laparoscopic Liver Biopsies in Pediatric Patients with Hepatic Dysfunction Following Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1147-1147.	0.6	0
123	A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. <i>Blood</i> , 2003, 101, 2476-2482.	0.6	155
124	Clinical applications of hematopoietic growth factors in pediatric oncology. <i>Current Opinion in Hematology</i> , 2002, 9, 222-227.	1.2	18
125	Transfusion-Associated Graft-vs-Host Disease. , 0, , 847-857.		1